Long‐standing prophylactic therapy vs. episodic treatment in young people with severe haemophilia: a comparison of age‐matched Danish and Russian patients

Two distinctly different substitution principles are commonly used in haemophilia: treatment at bleeding episodes only referred to as on‐demand treatment, and prophylactic factor administration. The aim of the cross‐sectional study which was undertaken in young patients suffering severe haemophilia A was to challenge our hypothesis that on‐demand treatment is inferior to prophylactic substitution in prevention of chronic joint disease at young age. The method involved an investigation of 40 patients from Russia (n = 27) and Denmark (n = 13) born between 1975 and 1990 with no history of inhibitors; Russian patients had exclusively received factor VIII on demand, while Danish patients were managed with prophylactic treatment during a mean period of 16 years since median age of 5 years. The study endpoints were clinical joint scores, Quality of Life scores and functional independence scores. Matched by identical age (±1 year) 13 Danish and 13 Russian patients were compared, while 14 age similar Russian patients served as controls. Demographic data among all groups were quite comparable. The results are that Russian patients presented with clinical joint scores at 27 ± 8.5 (mean ± SD) while matched Danish counterparts scored 3.8 ± 5.3 (mean ± SD), differences being highly significant. The number of joint bleeds in recent 5 years were 199.5 ± 135 (mean ± SD) vs. 8.1 ± 8.7 (mean ± SD). Likewise, Quality of Life and functional independence scores were significantly higher in patients on prophylaxis as compared to on‐demand treatment. In conclusion, the study outcomes confirmed our hypothesis. Longer term prophylactic factor administration during childhood and adolescence prevents joint destruction.

[1]  A. Iorio,et al.  Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. , 2011, The Cochrane database of systematic reviews.

[2]  J. Ingerslev,et al.  Utility of the Haemophilia Joint Health Score in study of episodically treated boys with severe haemophilia A and B in Lithuania , 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

[3]  M. Bullinger,et al.  Cross‐cultural development and psychometric evaluation of a patient‐reported health‐related quality of life questionnaire for adults with haemophilia , 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

[4]  Alan R. Cohen,et al.  Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. , 2007, The New England journal of medicine.

[5]  A. Iorio,et al.  Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. , 2006, The Cochrane database of systematic reviews.

[6]  C. Manigandan,et al.  Functional Independence Score in Haemophilia: a new performance‐based instrument to measure disability , 2005, Haemophilia : the official journal of the World Federation of Hemophilia.

[7]  J. Ingerslev,et al.  Tailoring haemostatic treatment to patient requirements – an update on monitoring haemostatic response using thrombelastography , 2005, Haemophilia : the official journal of the World Federation of Hemophilia.

[8]  K. Fischer,et al.  Can long‐term prophylaxis for severe haemophilia be stopped in adulthood? Results from Denmark and the Netherlands , 2005, British journal of haematology.

[9]  S. Israels,et al.  Home management of haemophilia , 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

[10]  B. Lindgren,et al.  On‐demand vs. prophylactic treatment for severe haemophilia in Norway and Sweden: differences in treatment characteristics and outcome , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

[11]  W. Gerbino,et al.  The joint. , 2003, Acta psychologica.

[12]  D. Grobbee,et al.  Prophylactic versus on‐demand treatment strategies for severe haemophilia: a comparison of costs and long‐term outcome , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

[13]  D. Grobbee,et al.  Prophylactic treatment for severe haemophilia: comparison of an intermediate‐dose to a high‐dose regimen , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

[14]  D. Grobbee,et al.  The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia. , 2002, Blood.

[15]  Gilbert Musculoskeletal complications of haemophilia: the joint , 2000, Haemophilia : the official journal of the World Federation of Hemophilia.

[16]  J. Astermark,et al.  Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized , 1999, British journal of haematology.

[17]  H. Pettersson,et al.  Twenty‐five years' experience of prophylactic treatment in severe haemophilia A and B , 1992, Journal of internal medicine.

[18]  Å. Ahlberg,et al.  HAEMOPHILIA PROPHYLAXIS IN SWEDEN , 1976, Acta paediatrica Scandinavica.